Disopyramide phosphate: Clinical efficacy of a new oral antiarrhythmic drug

Louis A. Vismara, Dean T. Mason, Ezra A Amsterdam

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The efficacy o f disopyramide phosphate (DP), a new oral antiarrhythmic agent, was evaluated by serial ten hour, portable electrocardiographic monitoring during placebo (P) and DP administration. In this 16 week outpatient study, DP therapy reduced the frequency of all cardiac ectopic depolarizations (ED) in 10 of 17 patients (average occurrence: P 145 per hour and DP 4 per hour, p < 0.05). Further, ventricular arrhythmias (VA): ventricular tachycardia (VT), and complicated VED, were recorded during P in 8 of 17 and in 16 of 17 patients, respectively, but this prevalence diminished with DP administration (VT 1 of 17, p < 0.05; VED 10 of 17 patients, p < 0.05). Atrial tachycardia (AT), noted in 6 patients during P, was abolished in 4 during active drug treatment. Despite minor anticholinergic adverse effects in 6 patients, DP was well tolerated in 17 of 18 patients and appeared safe even in 5 patients with cardiac decompensation prior to its administration.

Original languageEnglish (US)
Pages (from-to)330-335
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume16
Issue number2
StatePublished - Aug 1974

Fingerprint

Disopyramide
Anti-Arrhythmia Agents
Ventricular Tachycardia
Cholinergic Antagonists
Tachycardia
Cardiac Arrhythmias
Outpatients
Placebos
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Disopyramide phosphate : Clinical efficacy of a new oral antiarrhythmic drug. / Vismara, Louis A.; Mason, Dean T.; Amsterdam, Ezra A.

In: Clinical Pharmacology and Therapeutics, Vol. 16, No. 2, 08.1974, p. 330-335.

Research output: Contribution to journalArticle

@article{e20ce94610cc420a867f1fb5dd80e59f,
title = "Disopyramide phosphate: Clinical efficacy of a new oral antiarrhythmic drug",
abstract = "The efficacy o f disopyramide phosphate (DP), a new oral antiarrhythmic agent, was evaluated by serial ten hour, portable electrocardiographic monitoring during placebo (P) and DP administration. In this 16 week outpatient study, DP therapy reduced the frequency of all cardiac ectopic depolarizations (ED) in 10 of 17 patients (average occurrence: P 145 per hour and DP 4 per hour, p < 0.05). Further, ventricular arrhythmias (VA): ventricular tachycardia (VT), and complicated VED, were recorded during P in 8 of 17 and in 16 of 17 patients, respectively, but this prevalence diminished with DP administration (VT 1 of 17, p < 0.05; VED 10 of 17 patients, p < 0.05). Atrial tachycardia (AT), noted in 6 patients during P, was abolished in 4 during active drug treatment. Despite minor anticholinergic adverse effects in 6 patients, DP was well tolerated in 17 of 18 patients and appeared safe even in 5 patients with cardiac decompensation prior to its administration.",
author = "Vismara, {Louis A.} and Mason, {Dean T.} and Amsterdam, {Ezra A}",
year = "1974",
month = "8",
language = "English (US)",
volume = "16",
pages = "330--335",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Disopyramide phosphate

T2 - Clinical efficacy of a new oral antiarrhythmic drug

AU - Vismara, Louis A.

AU - Mason, Dean T.

AU - Amsterdam, Ezra A

PY - 1974/8

Y1 - 1974/8

N2 - The efficacy o f disopyramide phosphate (DP), a new oral antiarrhythmic agent, was evaluated by serial ten hour, portable electrocardiographic monitoring during placebo (P) and DP administration. In this 16 week outpatient study, DP therapy reduced the frequency of all cardiac ectopic depolarizations (ED) in 10 of 17 patients (average occurrence: P 145 per hour and DP 4 per hour, p < 0.05). Further, ventricular arrhythmias (VA): ventricular tachycardia (VT), and complicated VED, were recorded during P in 8 of 17 and in 16 of 17 patients, respectively, but this prevalence diminished with DP administration (VT 1 of 17, p < 0.05; VED 10 of 17 patients, p < 0.05). Atrial tachycardia (AT), noted in 6 patients during P, was abolished in 4 during active drug treatment. Despite minor anticholinergic adverse effects in 6 patients, DP was well tolerated in 17 of 18 patients and appeared safe even in 5 patients with cardiac decompensation prior to its administration.

AB - The efficacy o f disopyramide phosphate (DP), a new oral antiarrhythmic agent, was evaluated by serial ten hour, portable electrocardiographic monitoring during placebo (P) and DP administration. In this 16 week outpatient study, DP therapy reduced the frequency of all cardiac ectopic depolarizations (ED) in 10 of 17 patients (average occurrence: P 145 per hour and DP 4 per hour, p < 0.05). Further, ventricular arrhythmias (VA): ventricular tachycardia (VT), and complicated VED, were recorded during P in 8 of 17 and in 16 of 17 patients, respectively, but this prevalence diminished with DP administration (VT 1 of 17, p < 0.05; VED 10 of 17 patients, p < 0.05). Atrial tachycardia (AT), noted in 6 patients during P, was abolished in 4 during active drug treatment. Despite minor anticholinergic adverse effects in 6 patients, DP was well tolerated in 17 of 18 patients and appeared safe even in 5 patients with cardiac decompensation prior to its administration.

UR - http://www.scopus.com/inward/record.url?scp=0016166189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016166189&partnerID=8YFLogxK

M3 - Article

C2 - 4851400

AN - SCOPUS:0016166189

VL - 16

SP - 330

EP - 335

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -